Cutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and Digital Assessment Tools Used Today
BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ — Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based […]
Satio Successfully Completes Development and Testing of Novel At-Home, Remotely Controllable, Intradermal Drug Delivery System, Achieving the First Fully Executed ARPA-H Small Business Contract
BOSTON, April 7, 2025 /PRNewswire/ — Satio, Inc. is pleased to announce the successful completion of a Small Business Innovation Research contract awarded by the Advanced Research Projects Agency for Health (ARPA-H). The company’s ground-breaking SatioRx drug delivery device has been designed to provide stable and controlled delivery of liquid medicines through a hollow microneedle (HMN) […]
Small business research team develops low-cost reusable intradermal drug delivery device | ARPA-H
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today announced a commercially viable intradermal microneedle drug delivery device designed for home use. The project that developed this device is part of ARPA-H’s Small Business Innovation Research (SBIR) initiative to propel high-impact biomedical research […]
Satio Receives Funding From ARPA-H to Develop SatioRx™ a Novel At-home, Remotely Controllable Transdermal Drug Delivery Device
BOSTON, Sept. 26, 2023 /PRNewswire/ — Satio is pleased to announce a $3.5 million Small Business Innovation Research (SBIR) contract awarded by the Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services. This SatioRx™ device is designed to be compact and inexpensive, with disposable microneedle components that allow health care providers to remotely […]
Satio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnostic
Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic. This groundbreaking diagnostic will combine Satio’s patch-based blood collection device with Institut […]
Sapphiros Acquires Flexotronix Limited
Sapphiros has today completed the acquisition of Flexotronix Limited.
Satio and Institut Pasteur de Dakar Form Strategic Partnership on Research, Development, Manufacture, and Distribution of Next Generation Healthcare Technologies
The partnership aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.
Satio and INTACT Form Strategic Partnership to Jointly Improve Delivery of Mass Vaccination
Satio and INTACT Solutions have entered into an agreement to establish a collaborative framework in order to partner on research, development, manufacture, and deployment of next generation health technologies with the goal of offering alternative solutions to traditional needles with SatioRx™ intradermal patches for the Member States of the African Union and beyond.
The SatioPatch™ Platform provides consumer-based diagnosis and eliminates the need for needles administered by a medical professional.
Technology that allows real-time, accurate detection of a wide range of specific targets, and delivers results within minutes.